INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
03/05/2025
Voltar para busca
Dado oficial do USPTO
QUANTIPLEX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
47
Atualização mais recente
04/05/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5
Data de depósito
12/12/2012
Data de registro
24/09/2013
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
01/06/2024
Última transação
04/05/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
706
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
16
Localização do titular
Hilden, DE
Examinador
DIXON, JENNIFER
Localização atual
Historical data usage
Titulares e representantes
Titulares
QIAGEN GmbH
QIAGEN GmbH
Representantes
Victoria Friedman Dennemeyer & Associates, LLC
Classificação técnica
Classes Nice
Classe 1Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicalbiochemical and biotechnological products for industrial and scientific purposesdiagnostic preparations except for human or veterinary medical purposesnonmedical reagentsenzymes and buffer solutions for scientific and medical research use for sample preparationmodification and manipulation of cells and for conducting markingseparatingisolatingpurifyingduplicating and analyzing biopolymers in the nature of nucleic acidsproteinsmacromolecules and biologically active substancesreagentsenzymes and buffer solutions for nucleic acid amplification by polymerase chain reaction (PCR) ; kits comprising chemicals for sample preparationmodification and manipulation of cells and for markingseparatingisolatingpurifyingduplicating and analyzing biopolymers in the nature of nucleic acidsproteinsmacromolecules and biologically active substancesnucleic acids of biological or biochemical sample material comprising chemicals for reagentsenzymes and buffer solutions for nucleic acid amplification by polymerase chain reaction (PCR)
Classe 5
Diagnostic preparations for medical purposes; diagnostic preparations for veterinary purposes; diagnostic preparations for humans for medical purposes; preparations for medical and veterinary purposesdiagnostic preparations for sample preparationmodification and manipulation of cells and for markingseparatingisolatingpurifyingduplicating and analyzing biopolymers in the nature of nucleic acidsproteinsmacromolecules and biologically active substancesreagentsenzymes and buffer solutions for nucleic acid amplification by polymerase chain reaction (PCR); chemicalbiochemical and biotechnological preparationsreagentsenzymes and buffer solutions for sample preparationmodification and manipulation of cells and for conducting markingseparatingisolatingpurifyingduplicating and analyzing biopolymers in the nature of nucleic acidsproteinsmacromolecules and biologically active substances for diagnostic medical and clinical usereagentsenzymes and buffer solutions for nucleic acid amplification by polymerase chain reaction (PCR); kits containing preparations for medical and veterinary diagnostic purposesin particular for sample preparationmodification and manipulation of cells and for markingseparatingisolatingpurifyingduplicating and analyzing biopolymers in the nature of nucleic acids from biological or biochemical sample material for nucleic acid amplification by polymerase chain reaction (PCR)
Publicações
Histórico de despachos e eventos da marca no USPTO.
47 publicações encontradas
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
14/04/2025
INPC
INVALIDATION PROCESSED
14/04/2025
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
01/02/2025
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
01/06/2024
71AG
REGISTERED-SEC.71 ACCEPTED
01/06/2024
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
28/05/2024
PR71
POST REGISTRATION ACTION MAILED - SEC.71
13/05/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/05/2024
ES71
TEAS SECTION 71 RECEIVED
05/09/2023
RNWL
INTERNATIONAL REGISTRATION RENEWED
30/12/2022
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
24/09/2022
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
27/08/2019
C75A
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
27/08/2019
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
26/08/2019
ES75
TEAS SECTION 71 & 15 RECEIVED
31/07/2019
NREP
NEW REPRESENTATIVE AT IB RECEIVED
18/10/2018
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
24/09/2018
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
29/12/2014
NREP
NEW REPRESENTATIVE AT IB RECEIVED
22/08/2014
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
25/01/2014
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/01/2014
FIMP
FINAL DISPOSITION PROCESSED
09/01/2014
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
24/12/2013
R.PR
REGISTERED-PRINCIPAL REGISTER
24/09/2013
GPNX
NOTIFICATION PROCESSED BY IB
22/07/2013
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/07/2013
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/07/2013
PUBO
PUBLISHED FOR OPPOSITION
09/07/2013
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
19/06/2013
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
19/06/2013
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
19/06/2013
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
03/06/2013
ALIE
ASSIGNED TO LIE
31/05/2013
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
16/05/2013
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/05/2013
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/05/2013
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/05/2013
RFNP
REFUSAL PROCESSED BY IB
16/04/2013
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
25/03/2013
RFRR
REFUSAL PROCESSED BY MPU
25/03/2013
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
23/03/2013
CNRT
NON-FINAL ACTION WRITTEN
22/03/2013
DOCK
ASSIGNED TO EXAMINER
15/03/2013
MAFR
APPLICATION FILING RECEIPT MAILED
15/02/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/02/2013
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/02/2013
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace QUANTIPLEX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.